Index

A
Abdominal Aortic Aneurism (AAA) 8-10
Acute Lymphoblastic Leukemia (ALL) 114-116, 118, 120, 126, 146, 150-151, 157, 160-162, 168
Additive White Gaussian Noise (AWGN) 15
Additive White Gaussian Noise (AWGN) model 15
Adenosine Deaminase Deficiency-Related Severe Combined Immune Deficiency (ADA-SCID) 53
Adult Stem Cells 60
Adverse Drug Reactions (ADRs) 187-188, 192, 201
Allogenic Transplantation 55, 60
Allosteric Ribozymes 71-75, 77, 79-84, 86-88, 91-92
American Telemedicine Association (ATA) 203, 207
Amyotrophic Lateral Sclerosis (ALS) 53
Anatomical Therapeutic Chemical drug classification (ATC) group 191
aneurism 3, 8, 10-12, 25
antisense amplified RNA (aRNA) 123, 165
assessor 94, 106
autonomy 95, 173
averaged dot product 166

B
Bayesian Inference 1-3, 14, 17, 21, 25
Becker Muscular Dystrophy (BMD) 53
beneficence 95, 173
bifurcation analysis 61
bifurcation theory 61, 67, 70
bioethics 94-96, 109-110, 176

C
Cai’s TCM Gynecology 26, 47
cAMP-Responsive Element Binding Protein (CREB) 134, 136, 155
Cancer Germ-Line Gene (CGG) 168
Cancer Indicative RNAs 74-76
Captopril 192
cardio-toxicity 53
cardiovascular system 1-5, 7-8, 15, 18, 20, 23-24
cellular replacement therapy 52, 55, 60
cellular reprogramming 49, 51-52, 55, 60
Central Nervous System (CNS) 54
Chinese Medical Formula (CMF) 28-30, 36, 39-42
CHIP-chip (CHIP-on-chip) Microarrays 166
Chromatin Immunoprecipitation (ChIP) 122-124, 130, 166-167, 198
Chromosomal Microarray Analysis (CMA) 166
Cilazapril 192
closure analysis 127, 164, 166, 215, 218
clustering 121, 124-125, 127, 143, 166-167, 215
Committee of Publication Ethics (COPE) 2, 109
communications gap 213
communicative collaboration strategies 173
Comparative Genomic Hybridization (CGH) 122, 166
compartmentalisation 61-63, 67
complementary DNA (cDNA) 75, 92, 122-123, 158, 161, 164-165
compliance 5-6, 8, 11-12, 25, 100, 182, 191, 239
computational design of ribozymes 71, 89
Computer-Based Patient Record (CPR) technology 242
Condition 2, 4-5, 8, 10, 14, 20, 25, 65-66, 68, 84, 97, 114-115, 121, 221, 225, 247-248
Confirmatory Factor Analysis (CFA) 214
Continuous Quality Improvement (CQI) 203-204, 207
cosine correlation coefficient 166
Cy3 123-124, 166
Cy5 123-124, 166
Cyanine 166
Index

D

dangerous boundaries 66, 70
delivery gap 213
design gap 213
differentiation 49-50, 56, 60, 84, 88, 117-120, 129, 134, 136, 145-146, 151, 154, 158, 164
dimeric cytosolic 62
dimeric mitochondrial 63
dimeric nuclear 63
donated 102, 109, 207, 210, 218, 246, 252
dose 44, 187-188, 191-193, 199
DoseNumber 193
DoseVia 193
don Down Syndrome (DS) 53, 86
Duchenne (DMD) 53

E

eight inquiring 32
electronic lifetime health records 251
Embryonic Stem Cells (ESCs) 49-53, 55, 58-60, 163
enzyme reverse transcriptase (RT) 75
ethical requirements 170
ethics 94-95, 97-98, 100, 103, 105-110, 156, 170-172, 176, 253
Euclidean Distance 125, 166
Ewing Sarcoma/Primitive Neuroectodermal tumor (EWS/PNET) 120
exogenous control of gene expression 71, 73, 76, 80, 83-84, 86, 88, 92
exons 123, 165-166
expectation maximization (EM) algorithm 18
experience sharing 26, 28-29, 46-47
experiential learning 173-177
Exploratory Factor Analysis (EFA) 131, 213-214
Extended Kalman Filter (EKF) 15, 23

F

False Discovery Rate (FDR) 124, 134, 143, 168
Familial Dysautonomia (FD) 53, 58
fluorochromes 123, 166
Forward Scatter (FS) 126, 168

G

Gaucher disease (GD) type III 53
Gene Ontology (GO) 36, 39, 41, 121, 125, 129, 133-134, 137, 147, 165, 168, 173, 236, 250
genetic mutation 53, 74

Glia-Derived Neurotrophic Factor (GDNF) 54
Glomerular Filtration Rate (GFR) 191
gynecology 26-36, 42, 44-47

H

healthcare quality 95, 97-98, 100-107, 110, 170-171, 178-179, 184, 186, 242, 244-248, 252-253
healthcare quality improvement 101, 103-104, 110, 178, 184, 186
Health Insurance Portability and Accountability Act (HIPAA) 100, 110
health technology 23, 178, 180, 184-186
hemodynamic forward problem 25
hemodynamic inverse problem 1, 3, 6-7, 14-16, 20, 23, 25
hepatic toxicity 53
Hepatocellular Carcinoma (HCC) 69, 74, 83, 87
high-dimensional ODE system 6
Histone Deacetylase 7 (HDAC7) 155, 158
Hodgkin Lymphoma (HL) 74
Human Genome Project (HGP) 72
Huntington’s Disease (HD) 53
hybridization 75-76, 122-123, 166-167

I

Ill-posed 1, 14, 17, 25
Immediate Early (IE) genes 155
incident 235, 239, 241
Induced Pluripotent Stem Cells (iPSCs) 51-53, 55-60
Institute Of Medicine’s (IOM) 96-97, 103-104, 109, 253
Interleukins 145-146, 154
Internet of Things 187-189, 197, 199, 201
In Vitro 49-50, 52-53, 55-58, 60, 72-73, 77, 79-80, 85-86, 88, 92, 118-119, 123, 159, 161, 165
In Vitro Disease Modeling 53, 55, 57, 60
iPSC cells 49, 53, 58
Isogenic Transplantation (Autologous) 60

J

Jak-STAT 145, 149, 154-156
Justice 95, 98, 173, 185
Juvenile-Onset, Type 1 Diabetes Mellitus (JDM) 53

K

Kendall’s Tau 166
k-means clustering 125, 166-167
knowledge transfer 233-234, 236-237, 239-241
Index

L
listening and smelling 31-32
lumped parameter model 4

M
manhattan distance 166
Mantle Cell Lymphoma (MCL) 74, 83, 87, 89-91
M-A Plots 127, 130, 167
Mathematics for Diagnosis (M4D) 3
medical education 245, 249, 253
medical interpreter services 206
Microarray Technology (Chip) 122-124, 130, 166-167, 198
Mismatch (MM) 29, 76, 80, 121, 167, 213
Model-View-Controller (MVC) pattern 29
Monoamine Oxydase Type B (MAOB) 54
monomeric cytosolic 62
multiplexing technology 206
multipotency 60

N
next generation sequencing (NGS) technology 72
Near Field Communication (NFC) 187-188, 190, 195-202
nine inspection 31
nine palpation 32
Non-Hodgkin Lymphoma (NHL) 74
non-invasive hemodynamic measurements 1, 20
Non-Linear Steepest-Descent Algorithm (NLSD) 8, 12
non-maleficence 95
Non-Steroidal Anti-Inflammatory Drug (NSAID’s) 189-190, 200
normalization 17, 121-122, 124, 127, 131, 167
Nuclear Factor of Kappa in B-cells (NF-κB) 168
Nurse Educational Intervention 170-171

O
Object-Relational Mapping (ORM) 29
obligation for impartial quality assessment 94, 105, 110
online videoconferencing 249
Open Reading Frames (ORFs) 166
Ordinary Differential Equations (ODE) 4-6, 62-63

P
Parkinson’s Disease (PD) 49-51, 53-59
Partial Differential Equations (PDE) 4
patient-specific cardiovascular diagnosis 1, 20
pearson correlation 166
Perfect Match (PM) 167
personalized medicine 49
Pharmaceutical Intelligent Information System (PIIS) 188-190, 193, 196-199, 201
pharmaceuticals 53, 115, 183, 251
Picture Archiving and Communication Systems (PACS) 251
pluripotency 50-51, 60
potency 28, 49, 60, 158
Primitive Neuroectodermal Tumor (PNET) 120, 168
Principal Components Analysis (PCA) 125, 214
privacy rule 100, 110
Propidium Iodide (PI) 122, 168

Q
Quality-Adjusted Life Year (QALY) 98-99, 110
Quality Improvement (QI) strategy 247
quality of care 102, 109, 182, 205, 233-237, 239-240, 242, 244, 248, 252-253
Quinapril 192

R
Radio Frequency Identification (RFID) 187-189, 196-199, 201-202, 251
Ramipril 192
regenerative medicine 49-52, 56-57
regularization 14, 17, 25
reprogramming 49, 51-53, 55, 57, 59-60, 80
Rhabdomyosarcoma (RMS) 10-13, 111, 114-121, 126-127, 134, 150-151, 154-155, 160-164, 168
risk assessment 241
risk management 233-241
RNA interfering (RNAi) 74, 86, 88, 90

S
safe boundaries 66, 70
Selective Serotonin Reuptake Inhibitor (SSRI) 190
self-renewal 50-51, 60
Serum Response Elements (SREs) 155
Service Quality (SERVQUAL) 207, 209-216, 218-219
Shwachman-Bodian-Diamond Syndrome (SBDS) 53
Index

Side Scatter (SS) 126, 168
Simulated Annealing Algorithm (SA) 8, 158
Single Nucleotide Polymorphism (SNP) 72, 89, 91, 122
social accessibility 178
social inclusion 178, 184
socio-economic-medical-technological environment 97
Somatic Cell Nuclear Transfer (SCNT) 50, 55
spatial SERVQUAL model 209, 215
spearman rank-order correlation 166-167
specialized pedagogic environment 170
Spinal Muscular Atrophy (SMA) 53, 58
squared correlation coefficient 166
Standard of Care (SOC) 98
stem cell 49-51, 55, 57, 58-60, 74, 84, 88, 117-120, 134, 136, 145-146, 155, 159-161, 163, 168
stemness 156, 161, 168
stemness of cancer 168
stratifin 61
subcellular distribution 62
synthetic riboswitches 71-74, 80, 82-85, 87-88, 92

Total Quality Management (TQM) 181, 203-204, 238, 240
totipotency 60
Traditional Chinese Medicine (TCM) 26-29, 32, 35-38, 42, 44-47
Transcription Element Listening System (TELiS) Database 168
Transcription Factor Binding Motif (TFBM) 134, 154-155
Transcription Factors (TFs) 51, 89, 118, 125, 128, 134, 143, 154-155, 160, 165, 168
translocation 62, 66-68, 74, 151, 157

U
understanding gap 213
unipotency 60
Untranslated Region (UTR) 73

V
Virtual Campus Rhineland-Palatinate (VCRP) 249-250, 252

W
wearable technology 203, 206, 208
well-posed 14, 17, 25
Western Medicine (WM) 27-28, 32, 35, 39, 42, 44, 46
Wireless Local Area Network (W-LAN) 250
womb tumor 36, 42-44, 47